Recent Patents on Nasal Vaccines Containing Nanoadjuvants
Open Access
- 1 June 2022
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 16 (2) , 103-121
Abstract
Vaccines are one of the greatest medical achievements of modern medicine. The nasal mucosa represents an effective route of vaccination for both mucosal immunity and peripheral, being at the same time an inductive and effector site of immunity. In this paper, the innovative and patented compositions and manufacturing procedures of nanomaterials have been studied by using the peer-reviewed research literature. Nanomaterials have several properties that make them unique as adjuvants for vaccines. Nanoadjuvants through the influence of antigen availability over time affect the immune response. Namely, the amount of antigen reaching the immune system or its release over prolonged periods of time can be effectively increased by nanoadjuvants. Mucosal vaccines are an interesting alternative for immunization of diseases in which pathogens access the body through these epithelia. Nanometric adjuvants are not only a viable approach to improve the efficacy of nasal vaccines but in most cases represent the core of the intellectual property related to the innovative vaccine.Keywords
This publication has 88 references indexed in Scilit:
- Amyloidogenic Properties of a D/N Mutated 12 Amino Acid Fragment of the C-Terminal Domain of the Cholesteryl-Ester Transfer Protein (CETP)International Journal of Molecular Sciences, 2011
- Vaccination Strategies to Promote Mucosal Antibody ResponsesImmunity, 2010
- Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccinesNature Materials, 2010
- Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomesBMC Immunology, 2008
- The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting PriorMycobacterium bovisBCG Immunity toMycobacterium tuberculosisInfection and Immunity, 2007
- The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horsesVeterinary Immunology and Immunopathology, 2005
- Nanosphere Induced Gene Expression in Human Dendritic CellsNano Letters, 2005
- Stability of the C-terminal peptide of CETP mediated through an (i, i+4) arrayBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1998
- Biodegradable Long-Circulating Polymeric NanospheresScience, 1994
- The ISCOM: an immunostimulating complexImmunology Today, 1987